Header Logo

Connection

JASVINDER SINGH to Gout Suppressants

Back to Details
This is a "connection" page, showing publications JASVINDER SINGH has written about Gout Suppressants.
JASVINDER SINGH
Connection Strength
13.634
Gout Suppressants
  1. Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey. J Clin Rheumatol. 2020 Jun; 26(4):129-133.
    View in: PubMed
    Score: 0.670
  2. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. Ann Rheum Dis. 2020 04; 79(4):529-535.
    View in: PubMed
    Score: 0.655
  3. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. Eur Heart J. 2019 09 21; 40(36):3046-3054.
    View in: PubMed
    Score: 0.638
  4. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. J Rheumatol. 2020 03; 47(3):449-460.
    View in: PubMed
    Score: 0.634
  5. Goals of gout treatment: a patient perspective. Clin Rheumatol. 2018 Sep; 37(9):2557-2566.
    View in: PubMed
    Score: 0.590
  6. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis. Arthritis Res Ther. 2018 08 03; 20(1):167.
    View in: PubMed
    Score: 0.590
  7. Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults. Ann Rheum Dis. 2018 08; 77(8):1243-1245.
    View in: PubMed
    Score: 0.556
  8. Management of Gout. Ann Intern Med. 2017 06 06; 166(11):855.
    View in: PubMed
    Score: 0.544
  9. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017 Oct; 76(10):1669-1678.
    View in: PubMed
    Score: 0.544
  10. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure. Ann Rheum Dis. 2017 Jan; 76(1):133-139.
    View in: PubMed
    Score: 0.509
  11. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data. Ann Rheum Dis. 2017 Jan; 76(1):72-78.
    View in: PubMed
    Score: 0.505
  12. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015; 24(8):1013-30.
    View in: PubMed
    Score: 0.475
  13. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015 May 12; 17:120.
    View in: PubMed
    Score: 0.472
  14. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol. 2014 Apr; 20(3):172-4.
    View in: PubMed
    Score: 0.437
  15. Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout. J Rheumatol. 2014 Mar; 41(3):574-80.
    View in: PubMed
    Score: 0.430
  16. Emerging therapies for gout. Expert Opin Emerg Drugs. 2012 Dec; 17(4):511-8.
    View in: PubMed
    Score: 0.396
  17. Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. BMC Med. 2012 Feb 09; 10:15.
    View in: PubMed
    Score: 0.376
  18. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
    View in: PubMed
    Score: 0.361
  19. Advances in gout: some answers, more questions. Arthritis Res Ther. 2010; 12(5):136.
    View in: PubMed
    Score: 0.342
  20. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009 Apr; 11(2):154-60.
    View in: PubMed
    Score: 0.309
  21. SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol. Trials. 2021 Dec 04; 22(1):879.
    View in: PubMed
    Score: 0.186
  22. SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout. BMC Med. 2021 11 09; 19(1):265.
    View in: PubMed
    Score: 0.185
  23. Cardiovascular safety of febuxostat. Lancet. 2021 09 11; 398(10304):955.
    View in: PubMed
    Score: 0.183
  24. How do dietary interventions affect serum urate and gout? Nat Rev Rheumatol. 2021 04; 17(4):191-192.
    View in: PubMed
    Score: 0.177
  25. Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice. Clin Rheumatol. 2021 Feb; 40(2):693-700.
    View in: PubMed
    Score: 0.171
  26. Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills et al. Ann Rheum Dis. 2022 07; 81(7):e125.
    View in: PubMed
    Score: 0.168
  27. Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma et al. Ann Rheum Dis. 2022 06; 81(6):e108.
    View in: PubMed
    Score: 0.168
  28. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu et al. Ann Rheum Dis. 2022 07; 81(7):e123.
    View in: PubMed
    Score: 0.168
  29. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020 06; 72(6):879-895.
    View in: PubMed
    Score: 0.167
  30. Any sleep is a dream far away: a nominal group study assessing how gout affects sleep. Rheumatology (Oxford). 2018 11 01; 57(11):1925-1932.
    View in: PubMed
    Score: 0.150
  31. Association of Gout With Uveitis in Older Individuals. JAMA Ophthalmol. 2018 07 01; 136(7):835-837.
    View in: PubMed
    Score: 0.147
  32. Medication adherence among patients with gout: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018 04; 47(5):689-702.
    View in: PubMed
    Score: 0.139
  33. Gout Self-Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives. Arthritis Care Res (Hoboken). 2017 11; 69(11):1724-1732.
    View in: PubMed
    Score: 0.139
  34. EULAR gout treatment guidelines by Richette et al.: uric acid and neurocognition. Ann Rheum Dis. 2018 04; 77(4):e20.
    View in: PubMed
    Score: 0.134
  35. Chasing crystals out of the body: will treat to serum urate target for gout help us get there? Ann Rheum Dis. 2017 04; 76(4):629-631.
    View in: PubMed
    Score: 0.132
  36. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. J Clin Rheumatol. 2015 Dec; 21(8):411-8.
    View in: PubMed
    Score: 0.123
  37. OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol. 2014 Mar; 41(3):569-73.
    View in: PubMed
    Score: 0.107
  38. Outcome measures in acute gout: a systematic literature review. J Rheumatol. 2014 Mar; 41(3):558-68.
    View in: PubMed
    Score: 0.107
  39. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013 Feb; 15(2):307.
    View in: PubMed
    Score: 0.101
  40. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012 Jul; 39(7):1450-7.
    View in: PubMed
    Score: 0.096
  41. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012 May; 64(5):1508-17.
    View in: PubMed
    Score: 0.096
  42. Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. Ann Rheum Dis. 2011 Jul; 70(7):1277-81.
    View in: PubMed
    Score: 0.090
  43. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
    View in: PubMed
    Score: 0.090
  44. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
    View in: PubMed
    Score: 0.090
  45. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011 Jul; 50(7):1331-6.
    View in: PubMed
    Score: 0.088
  46. A national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management. Arthritis Care Res (Hoboken). 2010 Sep; 62(9):1306-11.
    View in: PubMed
    Score: 0.085
  47. Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Semin Arthritis Rheum. 2021 12; 51(6):1378-1385.
    View in: PubMed
    Score: 0.046
  48. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Semin Arthritis Rheum. 2018 10; 48(2):293-301.
    View in: PubMed
    Score: 0.036
  49. Renal dosing of allopurinol results in suboptimal gout care. Ann Rheum Dis. 2017 01; 76(1):e1.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.